IOVANCE BIOTHERAPEUTICS, INC.(IOVA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IOVA at 36.8/100 on a 32-signal composite quality model, placing it at rank #2,253 of 2,962 stocks — the bottom half of the AI-ranked universe. IOVA scores in the top quartile across revenue growth (99.3). Areas of concern include free cash flow (6.8) and balance sheet strength (7.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IOVANCE BIOTHERAPEUTICS, INC. reports quarterly revenue of $99.3M, net income of $-47.3M, free cash flow of $-66.3M. Top institutional holders of IOVA by reported 13-F value include BlackRock, MHR FUND MANAGEMENT, STATE STREET, based on the most recent SEC filings. IOVA trades on the Nasdaq exchange and files with the SEC under CIK 1425205. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IOVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IOVANCE BIOTHERAPEUTICS, INC. directly from SEC EDGAR.